Regenerative medicine firm ACell has enrolled the first patient for a US Phase IV clinical trial to assess the safety and long-term effectiveness of its MatriStem pelvic floor matrix device.

A total of 162 subjects will be recruited for the study in order to assess MatriStem’s ability to treat pelvic organ prolapse compared with native tissue repair.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The multi-centre, prospective, non-randomised trial will measure post-operative pelvic pain, quality of life and long-term need for retreatment.

The objective of the trial is to show that treatment with MatriStem Pelvic Floor Matrix device is effective to treat native tissue repair, as evaluated through anatomic and subjective assessments over a 36-month follow up period.

"This study will contribute to a better understanding of how physicians can help these patients achieve positive outcomes."

More than 300,000 cases of pelvic organ prolapse are treated surgically every year in the US. It is estimated that 20% of women will undergo one pelvic surgery in their lifetime.

The Phase IV trial is part of the company’s plan to carry out postmarket surveillance for MatriStem pelvic floor matrix in response to the 522 Order issued to all manufacturers of transvaginal pelvic meshes by the US Food and Drug Administration in January 2012.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

ACell CEO Jim DeFrancesco said: "ACell is proud to be partnering with an impressive group of surgeons to demonstrate the safety and effectiveness of MatriStem devices in pelvic floor repair."

The first patient in the trial was enrolled at Princeton Urogynecology under urogynecologist Heather van Raalte.

"Pelvic organ prolapse is a significant quality of life issue for hundreds of thousands of women," Raalte said

"This study will contribute to a better understanding of how physicians can help these patients achieve positive outcomes."

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact